Reductive activation with cysteine represents a chromium(III)-dependent pathway in the induction of genotoxicity by carcinogenic chromium(VI). by Zhitkovich, Anatoly et al.
Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 729
Hexavalent chromium compounds [Cr(VI)]
are recognized human and animal carcino-
gens (1,2). The cell transformation ability of
Cr(VI) is believed to result from its muta-
genic, clastogenic, and other genotoxic activ-
ities (3,4). Cr(VI) itself is unreactive toward
DNA at physiological pH and requires
reductive activation to produce DNA-dam-
aging species. The most important intracellu-
lar reducers of Cr(VI) are ascorbate and
nonprotein thiols such as glutathione and
cysteine (Cys) (5–7). The reductive metabo-
lism of Cr(VI) generates intermediate Cr(V)
and Cr(IV) forms and ﬁnally yields thermo-
dynamically stable Cr(III) (8,9). The relative
amount of these intermediate Cr forms varies
dramatically depending on the experimental
conditions, such as the nature of the reduc-
ing agent and its ratio to Cr(VI). Other
products of Cr(VI) reduction include sulfur-
and carbon-based radicals (9–11). Hydrogen
peroxide, either added intentionally or gener-
ated incidentally from iron-contaminated
reagents, is responsible for the formation of
hydroxyl radicals and Cr(V)-peroxo com-
plexes during reduction of Cr(VI) (10,12).
These unstable Cr intermediates and radical
species can potentially induce oxidation of
DNA (13), which could subsequently lead to
mutations and chromosomal damage. DNA-
damaging activity of hydroxyl radicals is well
known, whereas the reactivity of thiyl and
carbon-based radicals is expected to be much
lower (11,14). Treatment of cells or reduc-
tion of Cr(VI) in vitro also generates numer-
ous Cr–DNA adducts. These include binary
Cr(III)–DNA adducts, Cr(III)-mediated
DNA cross-links with Cys, histidine, or glu-
tathione (15), as well as interstrand DNA
cross-links (16). Ternary Cr(III)–DNA
adducts have been found to be mutagenic
during replication in human ﬁbroblasts (17).
The presence of several transient species
and the potential formation of both oxidative
and Cr–DNA lesions raise two important
questions: a) what is the nature of DNA-
attacking species, and b) what is the relative
signiﬁcance of oxidative and Cr(III)-dependent
pathways in the induction of genotoxicity by
Cr(VI)? To address these questions, we have
conducted detailed studies of Cys-based reac-
tions in which direct determinations of DNA
damage and the assessment of genotoxic conse-
quences were performed (18–20). Here, we
summarize our findings that nonoxidative
mechanisms involving Cr(III)–DNA binding
are responsible for the induction of the geno-
toxicity during reductive activation of Cr(VI)
by Cys.
Experimental Procedures
All buffers and reagents for electrophoresis
were from Sigma (St. Louis, MO, USA).
Chelex-100 resin and Bio-Gel P-30 columns
were obtained from Bio-Rad (Hercules, CA,
USA). K2CrO4 (A.C.S. reagent) was from
Aldrich (Milwaukee, WI, USA), 2´,7´-
dichloroﬂuoroscin diacetate was supplied by
Molecular Probes (Eugene, OR, USA).
Na2
51CrO4 and [35S]-labeled L-cysteine were
from Amersham (Arlington Heights, IL,
USA). ΦΧ 174 DNA was obtained from
New England Biolabs (Beverly, MA, USA).
L-Cysteine was from Gibco (Rockville, MD,
USA). All reagents were puriﬁed by Chelex-
100 chromatography as described previously
(18). Solutions of Cys were used within 30
min of preparation. A standard Cr(VI) reduc-
tion mixture contained 2 µg of supercoiled
pSP189 DNA, 25 mM 3-[N-morpholino]-
propanesulfonic acid (MOPS; pH 7.0), 2
mM Cys, and various concentrations of
K2CrO4 in a ﬁnal volume of 50 µL. In some
reactions 5 mM ethylenediamine tetraacetic
acid (EDTA) was also added or MOPS buffer
was replaced by 25 mM phosphate, 2-[N-
morpholino]ethanesulfonic acid (MES) or
HEPES (pH 7.0). Samples used for the
detection of DNA breakage contained 0.3 µg
of supercoiled Φ X174 DNA in a ﬁnal volume
of 25 µL. All samples were incubated for 60
min at 37°C, and DNA-unbound reactants
were removed by Bio-Gel P30 columns and
precipitation with ethanol. The amounts of
DNA-bound Cr and Cys were determined
using trace quantities of radioactive 51Cr-
chromate and 35S-Cys, respectively. The
number of interstrand DNA cross-links was
calculated from the relative amounts of dou-
ble-stranded DNA after denaturation in 0.2
M NaOH and separation of DNA by agarose
electrophoresis (18). Dissociation of DNA-
bound Cr was achieved by incubating
adducted DNA in the presence of 50 mM
sodium phosphate (pH 7.0) for 24 hr at 37°C
(19). Released Cr was removed by Bio-Gel
P30 columns. The presence of nicked DNA
was analyzed by agarose electrophoresis.
The genotoxic significance of DNA
damage arising from Cr(VI) reduction by Cys
was examined using the pSP189 shuttle-vector
This article is part of the monograph Molecular
Mechanisms of Metal Toxicity and Carcinogenicity.
Address correspondence to A. Zhitkovich, Dept. of
Pathology and Laboratory Medicine, Brown
University, Box G-B511, Providence, RI 02912
USA. Telephone: (401) 863-2912. Fax: (401) 863-
9008. E-mail: Anatoly_Zhitkovich@brown.edu
This work was supported by National Institute of
Environmental Health Sciences grant ES 08786.
Received 1 February 2002; accepted 29 May 2002.
Metals Toxicity
Induction of DNA damage by carcinogenic hexavalent chromium compounds [Cr(VI)] results
from its reduction to lower oxidation states. Reductive metabolism of Cr(VI) generates intermedi-
ate Cr(V/IV)species, organic radicals, and ﬁnally Cr(III), which forms stable complexes with many
biological ligands, including DNA. To determine the biological signiﬁcance of different reaction
products, we examined genotoxic responses and the formation of DNA damage during reduction
of Cr(VI) by its biological reducer, cysteine. We have found that cysteine-dependent activation of
Cr(VI) led to the formation of Cr–DNA and cysteine–Cr–DNA adducts as well as interstrand
DNA cross-links. The yield of binary and ternary DNA adducts was relatively constant at different
concentrations of Cr(VI) and averaged approximately 54 and 45%, respectively. Interstrand DNA
cross-links accounted on average for 1% of adducts, and their yield was even less signiﬁcant at low
Cr(VI) concentrations. Reduction of Cr(VI) in several commonly used buffers did not induce
detectable damage to the sugar–phosphate backbone of DNA. Replication of Cr(VI)-modified
plasmids in intact human fibroblasts has shown that cysteine-dependent metabolism of Cr(VI)
resulted in the formation of mutagenic and replication-blocking DNA lesions. Selective elimina-
tion of Cr–DNA adducts from Cr(VI)-treated plasmids abolished all genotoxic responses, indicat-
ing that nonoxidative, Cr(III)-dependent reactions were responsible for the induction of both
mutagenicity and replication blockage by Cr(VI). The demonstration of the mutagenic potential
of Cr–DNA adducts suggests that these lesions can be explored in the development of speciﬁc and
mechanistically important biomarkers of exposure to toxic forms of Cr. Key words: biomarker,
chromium, cysteine, DNA adduct, mutagenesis. Environ Health Perspect 110(suppl 5):729–731
(2002).
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(19). This vector is capable of replicating in
intact human cells, which permits its use for
the biological assessment of the presence of
mutagenic and replication-blocking DNA
lesions after in vitro treatments with Cr(VI).
In brief, control and Cr(VI)-treated plasmids
were transfected into human fibroblasts and
were allowed to replicate for 42–48 hr.
Replicated plasmids was isolated and then
used to transfect an indicator Escherichia coli
strain, MBL50. The efficiency of plasmid
replication in human cells was determined by
the number of E. coli transformants (ampi-
cillin-resistant colonies). The mutation fre-
quency at the supF gene was calculated by
dividing the number of arabinose/ampicillin-
resistant colonies by the number of ampicillin-
resistant colonies.
Results and Discussion
Kinetic studies of Cys-dependent reduction
of Cr(VI) at neutral pH have indicated that
the initial step in the reduction could proceed
through either one- or two-electron transfer
(20). The relative contribution of each reduc-
tion pathway depends on the concentration
of Cys, with one-electron transfer the domi-
nant mechanism in the physiological range of
Cys concentrations (>90% reduction).
Transfer of one electron to Cr(VI) would
generate a sulfur-based thiyl radical and
Cr(V) as the first products. Increased oxida-
tion of 2´,7´-dichloroﬂuoroscin in the reac-
tions containing low Cys concentrations was
consistent with the enhanced production of
Cr(V) under these conditions (20). The for-
mation of Cr(V) species and thiyl radicals in
Cr(VI)/Cys mixtures has been detected using
electron spin resonance (8,10). A second
reduction step most likely involves the pro-
duction of Cr(IV), but this has not yet been
established experimentally. Cr(III)–(Cys)2
complex was the major stable product of
Cr(VI) reduction by Cys (21). Addition of
DNA to the reduction mixtures resulted in
the formation of Cr(III)–DNA adducts (18).
Therefore, the induction of genotoxicity in
Cys-based reactions can potentially result
from oxidative damage by Cr(V) and thiyl
radicals or/and is caused by Cr(III)–DNA
binding.
The sugar–phosphate backbone of DNA
is one of the most common sites of damage
by oxidizing species. To detect the presence
of DNA-oxidizing activity in Cr(VI)–Cys
reactions, we analyzed the production of
DNA single-strand breaks (Figure 1A). No
signiﬁcant DNA breakage was detected using
sodium phosphate or three organic buffers.
Reduction of Cr(VI) in phosphate or MOPS
buffer using a 10-fold range of Cys concen-
trations also failed to produce abasic sites
(20). Thus, thiyl radicals and Cr(V) species
generated in Cr(VI)–Cys reactions appeared
unable to cause oxidative damage to the
sugar–phosphate backbone of DNA.
Reduction of Cr(VI) results in the forma-
tion of three types of Cr–DNA adducts:
binary Cr–DNA, ternary Cys–Cr(III)–DNA
adducts, and interstrand DNA cross-links
(18). Binary and ternary adducts represented
the majority of Cr–DNA complexes, and
their yield was essentially constant over a 25-
to 100-µM range of Cr(VI) (Figure 1B). The
average yields of binary and ternary DNA
adducts were 53.8 ± 1.8% and 45.3 ± 2.1%,
respectively. In contrast to monoadducts, the
formation of DNA–DNA cross-links was
progressively higher with increasing Cr(VI)
concentrations [0.2, 1.0, and 2.2% yield at
25, 50, and 100 µM Cr(VI), respectively].
Samples containing 10 µM Cr(VI) had unde-
tectable amounts of DNA cross-links (18).
Although DNA cross-links are considered to
be potent polymerase-blocking lesions (22),
their sparse formation at low concentrations
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Figure 2. Determination of genotoxic DNA damage using the pSP189 shuttle-vector. DNA modifications
were performed in the presence of 50 µM Cr(VI) and 2 mM Cys as described in Figure 1. DNA was puriﬁed
by Bio-Gel P-30 chromatography and ethanol precipitation and then transfected into human fibroblasts.
Mutation frequency and recovery of replicated plasmids were determined as described by Zhitkovich et
al. (19). Columns: I, Cr-untreated DNA; II, Cr(VI) reduction in 25 mM MOPS buffer; III, Cr(VI) reduction in 25
mM MOPS + 5 mM EDTA; IV, Cr(VI) reduction in 25 mM phosphate; V, Cr(VI) reduction in 25 mM MOPS fol-
lowed by dissociation of Cr from DNA in the presence of 50 mM phosphate (19). Shown are means ± SD
from six to eight independent experiments. (A) Cr–DNA binding. (B) Mutagenic responses. (C) Yield of
replicated plasmids.
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Figure 1. DNA damage resulting from Cr(VI) reduction by Cys. Each reaction mixture contained supercoiled
plasmid DNA, 25 mM buffer (pH 7.0), 2 mM Cys, and various concentrations of Cr(VI). Samples were incu-
bated for 60 min at 37°C and then analyzed for DNA breakage and Cr–DNA adducts. All determinations of
DNA adducts were performed using supercoiled pSP189 DNA. Overall yield of Cr adducts was determined
using 51Cr-chromate. The number of Cys–DNA cross-links was determined using 35S-Cys. Interstrand DNA
cross-links were quantiﬁed by renaturing agarose gel electrophoresis (18). DNA breakage was analyzed by
agarose electrophoresis of Φ X174 DNA. (A) DNA strand breakage: means from four independent experi-
ments. Error bars are not shown for clarity. (B) Yield of different Cr–DNA adducts. Percentage of each type
of adducts was calculated using mean values from four to six independent determinations.Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 731
of Cr(VI) suggests that these lesions are not
very likely to play a major role in the geno-
toxicity induced by Cys-dependent activation
of Cr(VI).
To determine whether reduction of
Cr(VI) in the presence of Cys produced
genotoxic DNA modiﬁcations, we employed
a pSP189 shuttle-vector approach (19). In
this assay, the pSP189 DNA is incubated in
Cr(VI)/Cys reduction mixtures, puriﬁed, and
then transfected into human cells to assess the
presence of premutagenic and replication-
blocking DNA lesions. Using this methodol-
ogy, it is possible to examine the importance
of different types of DNA damage by control-
ling their formation during in vitro reduction
of Cr(VI). Figure 2A shows that the forma-
tion of Cr–DNA adducts can be completely
blocked when reaction mixtures contained
the Cr(III)-chelating agents EDTA or inor-
ganic phosphate. We have also found (19)
that the majority of Cr(III)–DNA adducts
formed in the MOPS-based reactions can be
dissociated by the subsequent incubation in
the presence of 50 mM phosphate (Figure
2A, bar V). When pSP189 plasmids modiﬁed
in Cr(VI)–Cys reactions were replicated in
human ﬁbroblasts, we found a strong muta-
genic response in samples containing
Cr–DNA adducts but not in those lacking
them (Figure 2B). These results demonstrate
that Cys-dependent metabolism of Cr(VI)
did produce mutagenic DNA damage and
that Cr–DNA adducts were responsible for
the induction of mutagenicity. In addition to
mutagenic effects, Cr(VI)-induced damage
also caused a strong inhibition of plasmid
replication in intact human cells (Figure 2C,
bar II). Blocking of Cr(III)–DNA binding in
the reactions containing EDTA or phosphate
essentially restored template properties of
pSP189 plasmids. Release of approximately
80% of DNA-bound Cr by the treatment
with phosphate resulted in almost normal
yield of replicated plasmids, which further
conﬁrmed a critical role of Cr–DNA adducts
in the replication-blocking activity of Cr(VI).
The shuttle-vector experiments showed
that two very important forms of Cr(VI)/Cys-
induced genotoxicity, mutagenesis and repli-
cation blockage are caused by nonoxidative
mechanisms through the generation of
Cr(III)–DNA adducts (Figure 3). These ﬁnd-
ings provide an example of the biologically
relevant metabolic system in which
Cr(III)–DNA adducts are responsible for the
major genotoxic activities of Cr(VI). The
absence of detectable oxidative DNA damage
in Cr(VI)/Cys reactions indicates that thiyl
radicals and intermediate Cr(V/IV) forms are
relatively unreactive toward DNA. We expect
that the glutathione thiyl radical produced in
Cr(VI)/glutathione reactions (23) will have a
similarly low reactivity. The demonstration of
the mutagenic activity of Cr(III)–DNA
adducts identifies a biologically important
class of Cr(VI)-speciﬁc DNA lesions that can
be explored in the development of useful bio-
markers of exposure to toxic forms of Cr.
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Figure 3. Metabolism of Cr(VI) by Cys and the for-
mation of genotoxic DNA lesions.